

REMARKS

The final Office action mailed May 25, 2005 has been received and reviewed as has the Advisory Action mailed July 21, 2005. Claims 1-5 were finally rejected. Applicants have filed a Request for Continued Examination and are amending the application as previously set forth. The present amendment adds no new matter and remove the reference to "a peptide derivative thereof" from claims 1 and 5. All amendments are made without prejudice or disclaimer. Reconsideration is respectfully requested.

Claims 1 through 5 were rejected as being anticipated by U.S. Patent 5,677,725 to Lunardi-Iskandar. In view of the amendments to the claims, applicants respectfully request that the rejection be withdrawn.

Although it was acknowledged that the "oligopeptide" element of the claims distinguished from the reference (since the oligopeptide has at most 30 amino acids, wherein such a peptide is not disclosed in Lunardi-Iskandar), it was evidently believed that the peptide derivative of the oligopeptide might somehow have more than 30 amino acids. (Office Action, p. 4). Applicants have accordingly removed the "peptide derivative thereof" language from the claims, which should further distinguish the claims from the disclosure of Lunardi-Iskandar.

If questions should exist after consideration of the foregoing, the Office is kindly requested to contact applicants' undersigned attorney.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922
Facsimile: 801-531-9168

Date: August 5, 2005